SL-1-09

SL-1-09 is a second-generation flexible heteroarotinoid (Flex-Het) analog derived from the parental compound SHetA2. It is a racemic mixture of R (SL-1-29) and S (SL-1-30) enantiomers. Developed by researchers at Touro University and Dominican University of California, SL-1-09 exhibits potent anti-cancer activity against both estrogen receptor-positive (ERα+) and estrogen receptor-negative (ERα-) breast cancer cells. The compound inhibits breast cancer cell growth primarily by blocking cell cycle progression, which is associated with the down-regulation of key cell cycle regulatory proteins such as cyclin A, cyclin B, cyclin D1, cyclin E, and CDK2. The S enantiomer (SL-1-30) has been shown to possess greater growth inhibitory effects than the R enantiomer (SL-1-29).

Other names

1-(1-(naphthalen-1-yl)ethyl)-3-(4-nitrophenyl) thiourea1-(1-(naphthalen-1-yl)ethyl)-3-(4-nitrophenyl)thiourea